ArticleRheumatology and therapy2025

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme.

Ran Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.